aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
3DBio Therapeutics, founded with a mission to revolutionize regenerative medicine, specializes in precision bioprinting of living tissues. The company aims to replace individual patient parts with custom-designed tissues, leveraging advanced bioprinting technologies. Their core products and services include the GMPrint™ and ColVivo™ platforms, which are designed for the precise manufacturing of biologically compatible tissues. 3DBio focuses on the healthcare market, particularly in areas requiring tissue regeneration and repair.
Notable figures affiliated with 3DBio include experts in bioprinting and regenerative medicine, although specific names are not provided. The company has attracted significant investment from key players in the biotech industry. Among its achievements, 3DBio has developed proprietary cell processes and clinically tested bioprinting technologies that have shown promise in preclinical and clinical settings. The overall impact of 3DBio lies in its potential to transform patient-specific treatments through innovative tissue engineering solutions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Living Tissues
Technology
Biotech, Bioprinting
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was 3DBio founded?
3DBio was founded in 2014.
Where is 3DBio’s headquarters located?
3DBio’s headquarters is located in New York City, NY, US.
How many employees does 3DBio have?
3DBio has 39 employees as of Feb 4, 2024.
How much has 3DBio raised to-date?
As of July 05, 2023, 3DBio has raised a total of $500k (USD) since Apr 4, 2022.
Add Comparison
Total Raised to Date
$500k
USD
Last Update Apr 4, 2022
Total Employees Over Time
39
As of Feb 2024
3DBio Address
51-36 35th St
New York City,
New York
11101
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts